normorix mite tabletti
benzon pharma a/s - amiloridi hydrochloridum anhydricum,hydrochlorothiazidum - tabletti - hydroklooritiatsidi ja kaliumia säästävät diureetit
lorinid mite tabletti
alpharma aps - amiloridi hydrochloridum,hydrochlorothiazidum - tabletti - hydroklooritiatsidi ja kaliumia säästävät diureetit
hydrocal mite tabletti
pharmacal oy ab - amiloridi hydrochloridum dihydricum - tabletti - hydroklooritiatsidi ja kaliumia säästävät diureetit
hydrocal tabletti
pharmacal oy ab - amiloridi hydrochloridum dihydricum - tabletti - hydroklooritiatsidi ja kaliumia säästävät diureetit
moduretic tabletti
paranova oy - amiloridi hydrochloridum anhydricum,hydrochlorothiazidum - tabletti - hydroklooritiatsidi ja kaliumia säästävät diureetit
moduretic tabletti
merck sharp & dohme b.v. - hydrochlorothiazidum,amiloridi hydrochloridum - tabletti - hydroklooritiatsidi ja kaliumia säästävät diureetit
moduretic mite tabletti
merck sharp & dohme b.v. - hydrochlorothiazidum,amiloridi hydrochloridum anhydricum - tabletti - hydroklooritiatsidi ja kaliumia säästävät diureetit
normorix tabletti
benzon pharma a/s - hydrochlorothiazidum,amiloridi hydrochloridum anhydricum - tabletti - hydroklooritiatsidi ja kaliumia säästävät diureetit
lorinid tabletti
alpharma aps - hydrochlorothiazidum,amiloridi hydrochloridum - tabletti - hydroklooritiatsidi ja kaliumia säästävät diureetit
plerixafor accord
accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulantit, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.